John L. Marshall, MD, on Accessibility of Precision Medicine

Video

The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

In an article published in the journal Oncology®, John L. Marshall, MD, of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

“Cancer care can no longer be a luxury item, only for the rich. We must work toward wide access,” Marshall wrote. “Opening markets through collaborative science will secure the return on investment for our business partners, and secure our progress toward finding the cures for cancer.”

In an interview with CancerNetwork®, Marshall spoke about his paper further and why precision medicine will change global cancer care for decades to come.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

Marshall JL. The Prospective Incorporation of Molecular Profiling Will Transform Global Cancer Care. Oncology. https://www.cancernetwork.com/view/the-prospective-incorporation-of-molecular-profiling-will-transform-global-cancer-care

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.